论文部分内容阅读
目的探讨希罗达联合长春瑞滨(NX方案)和(或)多西他赛(TX方案)治疗晚期乳腺癌的临床疗效。方法选取2010年6月至2013年7月间内蒙古医科大学赤峰临床医学院肿瘤科收治的105例晚期女性乳腺癌患者。按入院顺序随机平均分为观察A组、观察B组和对照组,每组35例。观察A组采用NX方案治疗,观察B组患者采用TX方案治疗,对照组患者采用阿霉素联合环磷酰胺(AC方案)治疗,比较各组治疗效果、客观缓解率、不良反应和生存率。结果观察A组和观察B组完全缓解、部分缓解均显著高于对照组,病情稳定、疾病进展均显著低于对照组,差异均有统计学意义(均P<0.05)。观察A组和观察B组客观缓解率分别为68.6%和71.4%,均显著高于对照组的57.1%,差异均有统计学意义(均P<0.05)。观察A组和观察B组的1年生存率、2年生存率均显著高于对照组,差异均有统计学意义(均P<0.05)。观察A组与观察B组在不良反应、疗效、生存率、死亡率和中位疾病进展时间等方面比较,差异均无统计学意义(均P>0.05)。结论 NX方案和TX方案治疗晚期乳腺癌效果良好,客观缓解率比AC方案高,不良反应少,患者生存率高,值得临床推广。
Objective To investigate the clinical efficacy of Xeloda combined with vinorelbine (NX) and (or) docetaxel (TX) in the treatment of advanced breast cancer. Methods From June 2010 to July 2013, 105 patients with advanced breast cancer were admitted to Department of Oncology, Chifeng Clinical Medical College, Inner Mongolia Medical University. According to the order of admission randomly divided into observation A group, observation group B and control group, 35 cases in each group. The patients in group B were treated with TX regimen. The patients in control group were treated with doxorubicin combined with cyclophosphamide (AC regimen). The curative effect, objective response rate, adverse reactions and survival rate were compared between the two groups. Results The complete remission and partial remission in group A and group B were significantly higher than those in control group. The disease was stable and the disease progression was significantly lower than that in control group (all P <0.05). The objective response rates in observation group A and observation group B were 68.6% and 71.4%, respectively, which were significantly higher than those in control group (57.1%, both P <0.05). The 1-year survival rate and 2-year survival rate in observation group A and observation group B were significantly higher than those in control group (all P <0.05). There were no significant differences between the observation group A and the observation group B in adverse reactions, curative effect, survival rate, mortality and median disease progression time (all P> 0.05). Conclusion NX regimen and TX regimen are effective in treating advanced breast cancer. The objective response rate is higher than AC regimen, with fewer adverse reactions and high survival rate. It is worthy of clinical promotion.